Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis.
OBJECTIVE
This study evaluates the effectiveness of total pelvic exenteration with distal sacrectomy for fixed recurrent tumor that developed from primary rectal cancer.


METHODS
We investigated surgical indications, techniques to minimize blood loss and reduce complications, and oncological outcomes in 57 patients who underwent total pelvic exenteration with distal sacrectomy between 1983 and 2001.


RESULTS
Forty-eight patients (84 percent) had negative margins. A comparison between two periods (1983-1992 and 1993-2001) showed that mean blood loss decreased from 4,229 to 2,500 ml (P = 0.002), indicating a favorable learning curve in minimizing blood loss. Two hospital deaths were observed in the earlier period and none in the later period. The most common sacral amputation level was the S3 superior margin, followed by the S4 inferior margin and the S2 inferior margin. The most frequent complication was sacral wound dehiscence in 51 percent, followed by pelvic sepsis in 39 percent. The incidence of pelvic sepsis in the later period was significantly decreased to 23 percent, compared with 72 percent in the earlier period (P = 0.046). Multivariate analysis showed that negative margins and negative carcinoembryonic antigen predicted improved survival. In 48 patients with negative margins, three-year and five-year disease-specific survival rates were 62 percent and 42 percent, respectively.


CONCLUSIONS
Strict patient selection makes total pelvic exenteration with distal sacrectomy a feasible radical approach for fixed recurrent tumor. Careful performance of this surgical procedure along with the proper steps to decrease blood loss should achieve a favorable learning curve and low rate of surgical complications.
Moriya
Yoshihiro
Y
Department of Surgery, National Cancer Center Hospital, Tokyo, Japan.
Akasu
Takayuki
T
Fujita
Shin
S
Yamamoto
Seiichirou
S
D000328:Adult; D000368:Aged; D000671:Amputation, Surgical / Q000009:adverse effects / Q000379:methods*; D016063:Blood Loss, Surgical / Q000517:prevention & control / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery*; D009367:Neoplasm Staging; D010027:Osteotomy / Q000009:adverse effects / Q000379:methods*; D018579:Patient Selection; D010385:Pelvic Exenteration / Q000009:adverse effects / Q000379:methods*; D016016:Proportional Hazards Models; D012004:Rectal Neoplasms / Q000401:mortality / Q000601:surgery*; D012447:Sacrum / Q000294:innervation / Q000601:surgery*; D018805:Sepsis / Q000453:epidemiology / Q000209:etiology; D013529:Surgical Wound Dehiscence / Q000453:epidemiology / Q000209:etiology; D016019:Survival Analysis; D016896:Treatment Outcome